Part two of the latest Annual Report to the Nation on the Status of Cancer found that in 2019, the national patient economic burden associated with cancer care was $21.09 billion, made up of patient out-of-pocket costs of $16.22 billion and patient time costs—the value of time that patients spend traveling to and from, waiting for, and receiving care—of $4.87 billion.
In last week’s issue of The Cancer Letter, Raja Flores wrote a guest editorial explaining how he, with his expertise in thoracic surgery, took issue with a nuance in a recent Keytruda commercial.
